Craig Coleman, DO
Family Medicine · West Babylon, NYNPI 1154841617
Payments from drug & device makers
Across 218 payments — averaging $19.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$688
- Boehringer Ingelheim$507
- Merck$375
- Amgen$351
- Novo Nordisk$305
- Daiichi Sankyo Inc.$208
- plus $2K from 31 others
What the payments were for
- Food & beverage$4,23999%
- Education$501%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 29 | $688 |
| Boehringer Ingelheim | 29 | $507 |
| Merck | 20 | $375 |
| Amgen | 18 | $351 |
| Novo Nordisk | 18 | $305 |
| Daiichi Sankyo Inc. | 10 | $208 |
| Abbott | 9 | $185 |
| Exact Sciences | 9 | $171 |
| Lilly USA, LLC | 7 | $161 |
| Xeris Pharmaceuticals, Inc. | 9 | $155 |
| AbbVie | 7 | $146 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $109 |
| Amarin Pharma, Inc. | 4 | $90 |
| Currax Pharmaceuticals LLC | 4 | $83 |
| Pfizer | 5 | $73 |
| Mannkind Corporation | 3 | $69 |
| Amneal Pharmaceuticals LLC | 3 | $66 |
| Johnson & Johnson | 3 | $55 |
| Tandem Diabetes Care, Inc. | 2 | $49 |
| Boston Scientific | 2 | $47 |
| Bayer | 2 | $47 |
| Medtronic | 2 | $46 |
| Dexcom, Inc. | 2 | $40 |
| Idorsia Pharmaceuticals US Inc | 2 | $28 |
| Recordati_rare_diseases_inc. | 1 | $25 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $23 |
| Chiesi USA, Inc. | 1 | $22 |
| Insulet Corporation | 1 | $21 |
| Scpharmaceuticals Inc. | 1 | $20 |
| Ultragenyx Pharmaceutical Inc. | 1 | $20 |
| Zealand Pharma US, Inc. | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Vistapharm, Inc. | 1 | $15 |
| GSK | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Phadia US Inc. | 1 | $13 |
How this compares
$4,289 in reported general payments places this provider in the 85th percentile of 4,321 family medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 97 | $91,466 |
| OzempicSemaglutide | 49 | $74,578 |
| XareltoRivaroxaban | 34 | $44,484 |
| JardianceEmpagliflozin | 22 | $37,213 |
| JanuviaSitagliptin Phosphate | 27 | $31,906 |
| MounjaroTirzepatide | 20 | $24,147 |
| EntrestoSacubitril/Valsartan | 18 | $18,687 |
| WegovySemaglutide | 12 | $15,376 |
| Metformin Hcl | 127 | $14,994 |
| Breo ElliptaFluticasone/Vilanterol | 36 | $14,763 |
| RybelsusSemaglutide | 16 | $14,643 |
| Tresiba Flextouch U-100Insulin Degludec | 22 | $13,930 |
| MyrbetriqMirabegron | 13 | $12,589 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $11,204 |
| FarxigaDapagliflozin Propanediol | 13 | $10,777 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Wegovy, Rybelsus | $305 | $104,59777 claims |
| PfizerEliquis | $73 | $91,46697 claims |
| Johnson & JohnsonXarelto | $55 | $44,48434 claims |
| Boehringer IngelheimJardiance | $507 | $37,21322 claims |
| MerckJanuvia | $375 | $31,90627 claims |
| GSKBreo Ellipta, Trelegy Ellipta | $15 | $25,96749 claims |
| Lilly USA, LLCMounjaro | $161 | $24,14720 claims |
| NovartisEntresto | $688 | $18,68718 claims |
| AbbVieSynthroid | $146 | $4,10856 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $66 | $2,028177 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,321 family medicine providers in New York.
Other family medicine in West Babylon
- Robert SicaWest Babylon$51K
- Matthew DavisRochester$76.6M
- Frank EderBinghamton$46.2M
- Suchet PatelEndwell$23.3M
- James WildGowanda$2.2M
- Michael FedericoEndwell$1.4M
- Donald BrautigamWestfield$1.3M
- Kimberly DesantisEndwell$1.1M
- Michael TugetmanHartsdale$1M
- Richard RuhOrchard Park$769K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.